Cited by 190Glioma Diagnosis and TreatmentNanoparticle-Based Drug DeliveryDrug Transport and Resistance Mechanisms

The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.

Phase I Study of GRN1005 in Recurrent Malignant Glioma

Drappatz, Jan, Brenner, Andrew, Wong, Eric T., Eichler, April, Schiff, David, Groves, Morris D., Mikkelsen, Tom, Rosenfeld, Steve, Sarantopoulos, John, Meyers, Christina A., Fielding, Robert M., Elian, Kelly, Wang, Xiaolin, Lawrence, Betty, Shing, Mona, Kelsey, Stephen, Castaigne, Jean Paul, Wen, Patrick Y.·2013·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-12-2481

Open this paper in CoChat — free account

Abstract

PURPOSE: GRN1005 is a peptide-drug conjugate with the ability to penetrate the blood-brain barrier (BBB) and tumor cells by targeting the low-density lipoprotein receptor-related protein-1. We conducted a first-in-human phase I trial of GRN1005 in patients with recurrent glioma. METHODS: Patients received GRN1005 by intravenous infusion every 3 weeks. Doses were escalated using a modified Fibonacci scheme. Study objectives included safety, tolerability, identification of the maximum tolerated dose (MTD), pharmacokinetics, and preliminary evidence of efficacy. Tumor extracted from patients undergoing surgery following administration of GRN1005 was analyzed to determine whether therapeutic concentrations of GRN1005 were achieved. RESULTS: Sixty-three patients received GRN1005 at doses of 30 to 700 mg/m(2) every 3 weeks. Therapy was well tolerated with neutropenia, leucopenia, and fatigue as the most frequent drug-associated grade 3/4 or higher toxicities. The MTD was 650 mg/m(2) every 3 weeks. Dose-limiting toxicities were grade 3 mucositis and grade 4 neutropenia. There was no evidence of central nervous system toxicity or antibody production. Pharmacokinetic analysis showed that exposure to GRN1005 was dose proportional. We observed one complete and two partial responses. Eight of 27 patients dosed ≥ 420 mg/m(2) had stable disease, which lasted a median of 51 days. Therapeutic concentrations of GRN1005 and free paclitaxel were shown in tumor tissue of surgical patients dosed with ≥ 200 mg/m(2). CONCLUSION: GRN1005 delivers paclitaxel across the BBB and achieves therapeutic concentrations in tumor tissue. It has similar toxicity to paclitaxel and appears to have activity in recurrent glioma. The recommended phase II dose is 650 mg/m(2) every 3 weeks.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-12-2481

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Malignant Gliomas in Adults
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Self-citation
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N. A., Nicholas, M. K., Jensen, R. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,516
Self-citation
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M. A., Butman, J. A., Camphausen, K. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,567
Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings.
Aronen, H. J., Gazit, I. E., Louis, D. N., Buchbinder, B. R., Pardo, F. S., Weisskoff, R. M., Harsh, G. R., Cosgrove, G. R., Halpern, E. F., & Hochberg, F. H. (1994) · Radiology · doi:10.1148/radiology.191.1.8134596 · Cited by 905
LDL Receptor-Related Protein 1: Unique Tissue-Specific Functions Revealed by Selective Gene Knockout Studies
Lillis, A. P., Van Duyn, L. B., Murphy-Ullrich, J. E., & Strickland, D. K. (2008) · Physiological Reviews · doi:10.1152/physrev.00033.2007 · Cited by 669
Involvement of the low‐density lipoprotein receptor‐related protein in the transcytosis of the brain delivery vector Angiopep‐2
Demeule, M., Currie, J., Bertrand, Y., Ché, C., Nguyen, T., Régina, A., Gabathuler, R., Castaigne, J., & Béliveau, R. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05492.x · Cited by 557
Self-citation
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
Wick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L., Mason, W. P., Weller, M., Hong, S., Musib, L. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2595 · Cited by 518

Show all 51 references

Sorted by citations

Items 101–189 of 189

The development of peptide-drug conjugates (PDCs) strategies for paclitaxel
Wang, L., Chen, H., Wang, F., & Zhang, X. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2039621 · Cited by 26
Neuroglia as targets for drug delivery systems: A review
Madhusudanan, P., Reade, S., & Shankarappa, S. A. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.08.013 · Cited by 26
Peptides in clinical development for the treatment of brain tumors
Guidotti, G., Brambilla, L., & Rossi, D. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.02.007 · Cited by 26
Recent progress in the development of peptide-drug conjugates (PDCs) for cancer therapy
He, H., Deng, X., Wang, Z., & Chen, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117204 · Cited by 25
Cell-penetrating peptides improve pharmacokinetics and pharmacodynamics of anticancer drugs
Rusiecka, I., Gągało, I., & Kocić, I. (2021) · Tissue Barriers · doi:10.1080/21688370.2021.1965418 · Cited by 25
Recent Advances in Augmenting the Therapeutic Efficacy of Peptide–Drug Conjugates
Ma, J., Wang, X., Hu, Y., Ma, J., Ma, Y., Chen, H., & Han, Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00007 · Cited by 24
Self-citation
An Insight into Molecular Targets of Breast Cancer Brain Metastasis
Kaleem, M., Dalhat, M. H., Azmi, L., Asar, T. O., Ahmad, W., Alghanmi, M. S., Almostadi, A., Zughaibi, T. A., & Tabrez, S. S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911687 · Cited by 23
Glioblastoma Therapy: Rationale for a Mesenchymal Stem Cell-based Vehicle to Carry Recombinant Viruses
Ali, S., Qin, X., Muhammad, T., Liu, L., Meng, X., Bars‐Cortina, D., Khan, A. A., Huang, Y., & Dong, L. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10207-w · Cited by 23
Targeting central nervous system pathologies with nanomedicines
Mizrahy, S., Gutkin, A., Decuzzi, P., & Peer, D. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1533556 · Cited by 22
Development of bioactive materials for glioblastoma therapy
Yang, J., Li, Y., Zhang, T., & Zhang, X. (2016) · Bioactive Materials · doi:10.1016/j.bioactmat.2016.03.003 · Cited by 20
Modélisationin vitrode la barrière hémato-encéphalique
Gosselet, F. (2017) · médecine/sciences · doi:10.1051/medsci/20173304013 · Cited by 23
Phase II trial of blood–brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma
Dmello, C., Brenner, A. J., Piccioni, D. E., Wen, P. Y., Drappatz, J., Mrugala, M. M., Lewis, L. D., Schiff, D., Fadul, C. E., Chamberlain, M. C., et al. (2024) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdae186 · Cited by 19
Self-citation
Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review
Gunjur, A., Balasubramanian, A., Hafeez, U., Menon, S., Cher, L., Parakh, S., & Gan, H. K. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-04092-7 · Cited by 18
Development of membrane‐active peptide therapeutics in oncology
Chen, C. H., Zan, B., Ulmschneider, J. P., Wimley, W. C., Lu, T. K., Ulmschneider, M. B., & Zhou, L. (2023) · Journal of Peptide Science · doi:10.1002/psc.3482 · Cited by 18
Comprehensive insights into glioblastoma multiforme: drug delivery challenges and multimodal treatment strategies
Dhiman, A., Rana, D., Benival, D. M., & Garkhal, K. (2024) · Therapeutic Delivery · doi:10.1080/20415990.2024.2415281 · Cited by 20
Brain-Penetrating Peptide Shuttles across the Blood–Brain Barrier and Extracellular-like Space
Peng, X., Liu, X., Kim, J. Y., Nguyen, A., Leal, J., & Ghosh, D. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00446 · Cited by 19
An Amyloid-β Targeting Chemical Exchange Saturation Transfer Probe for In Vivo Detection of Alzheimer’s Disease
Wang, R., Wang, C., Dai, Z., Chen, Y., Shen, Z., Xiao, G., Chen, Y., Zhou, J., Zhuang, Z., & Wu, R. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00334 · Cited by 17
Strategies to target drugs to gliomas and CNS metastases of solid tumors
Kerklaan, B. M., van Tellingen, O., Huitema, A. D. R., Beijnen, J. H., Boogerd, W. J., Schellens, J. H. M., & Brandsma, D. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7919-9 · Cited by 16
Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy
Shen, X., Ma, Y., Luo, H., Abdullah, R., Pan, Y., Zhang, Y., Zhong, C., Zhang, B., & Zhang, G. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics17010040 · Cited by 18
Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy
Najem, H., Khasraw, M., & Heimberger, A. B. (2021) · Cells · doi:10.3390/cells10082032 · Cited by 17
Drug delivery to the brain
Khosa, A., Saha, R. N., & Singhvi, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816505-8.00005-9 · Cited by 16
Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma
Dmello, C., Sonabend, A., Arrieta, V. A., Zhang, D. Y., Kanojia, D., Chen, L., Gould, A., Zhang, J., Kang, S. J., Winter, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2563 · Cited by 15
Generation of KS-487 as a novel LRP1-binding cyclic peptide with higher affinity, higher stability and BBB permeability
Sakamoto, K. (2022) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2022.101367 · Cited by 15
A peptide-based near-infrared fluorescence probe for dynamic monitoring senile plaques in Alzheimer’s disease mouse model
Wang, C.-W., Nan, D., Wang, X.-M., Ke, Z., Chen, G., & Zhou, J. (2017) · 中国科学通报：英文版 · doi:10.1016/j.scib.2017.11.005 · Cited by 16
Self-citation
New therapeutic strategies regarding endovascular treatment of glioblastoma, the role of the blood–brain barrier and new ways to bypass it
Peschillo, S., Caporlingua, A., Diana, F., Caporlingua, F., & Delfini, R. (2015) · Journal of NeuroInterventional Surgery · doi:10.1136/neurintsurg-2015-012048 · Cited by 14
Recent Progress in Peptide-Based Fluorescent Probes Biomedical Applications: A Review
Zhong, X., Xie, Y., Chen, Y., Lu, Y., & Hou, M. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s529323 · Cited by 13
Bridging the blood-brain barrier: strategies to improve delivery of biologics to tumors in the brain
Gampa, G., Vadlakonda, R., Stefanich, E. G., Kamath, A. V., Sadekar, S., & Shivva, V. (2026) · Fluids and Barriers of the CNS · doi:10.1186/s12987-026-00760-2 · Cited by 13
Polymer nanocarriers for targeted local delivery of agents in treating brain tumors
Josowitz, A. D., Bindra, R. S., & Saltzman, W. M. (2022) · Nanotechnology · doi:10.1088/1361-6528/ac9683 · Cited by 12
Pathways for Drug Delivery to the Central Nervous System
On, N. H., Yathindranath, V., Sun, Z., & Miller, D. W. (2016) · Drug Delivery · doi:10.1002/9781118833322.ch16 · Cited by 11
Imaging of brain clearance pathways via MRI assessment of the glymphatic system
He, Y., Guan, J., Lai, L., Zhang, X., Chen, B., Wang, X., & Wu, R. (2023) · Aging · doi:10.18632/aging.205322 · Cited by 9
Self-citation
Exploring Novel Molecular Targets for the Treatment of High-Grade Astrocytomas Using Peptide Therapeutics: An Overview
Guidotti, G., Brambilla, L., & Rossi, D. (2020) · Cells · doi:10.3390/cells9020490 · Cited by 9
Blood-Brain Barrier (BBB)-Crossing Strategies for Improved Treatment of CNS Disorders
Zhang, W. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_689 · Cited by 8
Technology and precision therapy delivery in childhood cancer
Tydings, C., & Kim, A. (2019) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000865 · Cited by 8
The Strategies of Nanomaterials for Traversing Blood-Brain Barrier
Rauf, M. A., Rehman, F. U., Zheng, M., & Shi, B. (2019) · Springer eBooks · doi:10.1007/978-981-13-8731-9_2 · Cited by 8
Novel Chemotherapeutic Approaches in Adult High-Grade Gliomas
Jordan, J. T., & Wen, P. Y. (2014) · Cancer treatment and research · doi:10.1007/978-3-319-12048-5_8 · Cited by 8
Self-citation
MT1-MMP Expression Levels and Catalytic Functions Dictate LDL Receptor-Related Protein-1 Ligand Internalization Capacity in U87 Glioblastoma Cells
Pratt, J., Haidara, K., & Annabi, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214214 · Cited by 8
Clinical Trials in the Brain Tumour Population: Challenges and Strategies for the Future
Gan, H. K., Day, B. W., Harrup, R. A., Johns, T. G., Lwin, Z., Scott, A. M., Sim, H., & Koh, E. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01394-5 · Cited by 8
Clinical Trials for Breast Cancer with Brain Metastases: Challenges and New Directions
Morikawa, A., Jhaveri, K. L., & Seidman, A. D. (2013) · Current Breast Cancer Reports · doi:10.1007/s12609-013-0120-1 · Cited by 7
Antibody drug conjugates for glioblastoma: current progress towards clinical use
Gan, H. K., Parakh, S., Osellame, L. D., Cher, L., Uccellini, A., Hafeez, U., Menon, S., & Scott, A. M. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2282729 · Cited by 8
Neuro-oncology biotech industry progress report
Chakraborty, S., Bodhinayake, I., Chiluwal, A., Langer, D. J., Ruggieri, R., Symons, M. H., & Boockvar, J. A. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2087-z · Cited by 7
Polymeric Nanoparticles Revolutionizing Brain Cancer Therapy: A Comprehensive Review of Strategies and Advances
Wahengbam, G. S., Nirmal, S., Nandwana, J., Kar, S., Kumari, V., Mishra, R., & Singh, A. (2024) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2024051822 · Cited by 7
Green chemistry: Modern therapies using nanocarriers for treating rare brain cancer metastasis from colon cancer
Khafaga, D. S. R., Muteeb, G., Aswa, D. W., Aatif, M., Farhan, M., & Allam, S. (2025) · SLAS DISCOVERY · doi:10.1016/j.slasd.2025.100213 · Cited by 6
Brain Drug Delivery: Overcoming the Blood-brain Barrier to Treat Tauopathies
Hanes, J., Dobáková, E., & Majerová, P. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200316130128 · Cited by 6
The Application of Peptides in Glioma: A Novel Tool for Therapy
Li, L., Chen, J., Ming, Y., Li, B., Fu, R., Duan, D., Li, Z., Ni, R., Wang, X., Zhou, Y., et al. (2021) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201022666210628114042 · Cited by 6
Self-citation
Simplifying synthesis of the expanding glioblastoma literature: a topic modeling approach
Karabacak, M., Jagtiani, P., Carrasquilla, A., Jain, A., Germano, I. M., & Margetis, K. D. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04762-8 · Cited by 5
Membrane-active peptides for anticancer therapies
Chen, C. H. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.10.005 · Cited by 4
Engineering the blood–brain barrier on chip: advances in preclinical drug penetration and disease modeling
Sissoko, C. A., Spitz, S., Zhang, Z., Abedi, K., Kamm, R. D., & Barrile, R. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115881 · Cited by 6
Influence of transporters in treating cancers in the CNS
Gampa, G., Talele, S., Kim, M., Mohammad, A. S., Griffith, J. I. G., & Elmquist, W. F. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816434-1.00009-7 · Cited by 4
Nanotechnology in Brain Tumor Targeting
Lalatsa, A., Leite, D. M., Figueiredo, M. F., & O’Connor, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812218-1.00005-1 · Cited by 5
Nanomedicine Applications in Treatment of Primary Central Nervous System Lymphoma: Current State of the Art
Wang, M., Qu, Y., Hu, D., Niu, T., & Qian, Z. (2021) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2021.3133 · Cited by 4
AI-Driven Design and Clinical Translation of Nucleotide−Peptide and Peptide−Drug Conjugates
Pandey, K., Dave, R., Patel, R., Verma, S. K., Solanki, R., Yadav, A. K., Gour, N., & Bhatia, D. D. (2026) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.6c00187 · Cited by 3
Polypeptide-modified black phosphorus nanosheets as a brain-targeted neuroprotective agent for treating ischemic stroke
Zhang, M., Fan, T., Yin, S., Li, J., Hou, J., Zhang, K., Han, B. R., Chen, W., Zhang, H., & Tian, X. (2025) · Bio-Design and Manufacturing · doi:10.1631/bdm.2400176 · Cited by 3
Drug Delivery to Primary and Metastatic Brain Tumors: Challenges and Opportunities
Talele, S., Mohammad, A. S., Schulz, J., Bauer, B., Hartz, A. M. S., Sarkaria, J. N., & Elmquist, W. F. (2022) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-88773-5_24 · Cited by 3
Glioma targeted delivery systems
Wang, S., Li, C., Qian, M., & Huang, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814001-7.00012-3 · Cited by 3
Nanomicellar Prodrug Delivery of Glucose-Paclitaxel: A Strategy to Mitigate Paclitaxel Toxicity
Yan, D., Ma, X., Hu, Y., Zhang, G., Hu, B., Xiang, B., Cheng, X., Jing, Y., & Chen, X. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s500999 · Cited by 2
Peptide–drug conjugates: Emerging strategies in glioma therapy
Yun, D., Mu, L., Liu, J., Zhao, S., Li, C., Zhai, Q., Sun, H., Wu, X., Shi, K., & Fan, W. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109382 · Cited by 2
TRAIL as a Warrior in Nano-Sized Trojan Horse: Anticancer and Anti-Metastatic Effects of Nano-Formulations of TRAIL in Cell Culture and Animal Model Studies
Farooqı, A. A., Turgambayeva, A. K., Маратовна, К. Г., Suleimenova, R. K., Latypova, N., Ospanova, S., Ospanova, D., Abdikadyr, Z., & Zhussupov, S. M. (2024) · Medicina · doi:10.3390/medicina60121977 · Cited by 2
Selecting Peptides for Targeted Delivery of Drugs Inside Cancer Cells
Kalishwaralal, K., Abhishek, A., Sharma, S., & Firer, M. A. (2025) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-025-10712-3 · Cited by 2
Angiopep-2 as an Exogenous Chemical Exchange Saturation Transfer Contrast Agent in Diagnosis of Alzheimer’s Disease
Wang, C., Lin, G., Shen, Z., & Wang, R. (2022) · Journal of Healthcare Engineering · doi:10.1155/2022/7480519 · Cited by 2
Retracted
Does interventional MRI-guided brain cryotherapy cause a blood–brain barrier disruption? Radiological analysis and perspectives
Mallereau, C.-H., Baloglu, S., Chibbaro, S., Noblet, V., Todeschi, J., Noël, G., Gangi, A., de Mathelin, M., Proust, F., & Cébula, H. (2021) · Neurosurgical Review · doi:10.1007/s10143-021-01637-8 · Cited by 2
Brain tumors – other treatment modalities
Peyrl, A., Frischer, J. M., Hainfellner, J. A., Preusser, M., Dieckmann, K. U., & Marosi, C. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802395-2.00034-1 · Cited by 3
Peptide Therapeutics
Fotouhi, N. (2015) · doi:10.1002/9781118995303.ch1 · Cited by 2
Glioma drug development benefits from emerging phase 0 and window-of-opportunity trial paradigm
Jiang, S., & Zhong, C. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02408-4 · Cited by 1
Biofabrication of 3D bioprinted and organ-on-chip blood–brain barrier models using hCMEC/D3 for intranasal delivery of central nervous system therapeutics
Wong, C. Y. J., Pannadewi, T., Khan, T. T. S., Ong, H. X., & Traini, D. (2026) · Biofabrication · doi:10.1088/1758-5090/ae3526 · Cited by 2
Hyaluronic acid–based systems for brain drug delivery: bridging material design and cellular response
Serri, C., Langellotto, M. D., Arshad, S. G., Piccioni, M., Scialla, S., Mola, A. D., Sportiello, P., Rassu, G., Massa, A., Crispi, S., et al. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2642105 · Cited by 2
Medicinal Chemistry and Brain Drug Penetrance
Hilaire, J. R., & Gendelman, H. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_49 · Cited by 1
Strategies to Modulate the Blood-Brain Barrier for Directed Brain Tumor Targeting
Schiapparelli, P. V., Lara-Velazquez, M. A., Al‐kharboosh, R., Su, H., Cui, H., & Quiñones‐Hinojosa, A. (2020) · Neuromethods · doi:10.1007/978-1-0716-1052-7_3 · Cited by 1
Trends in Peptide Therapeutics
Brunel, F. M., Liu, F., & Mayer, J. P. (2019) · doi:10.1002/9783527814695.ch1 · Cited by 1
Novel Delivery Strategies
Hersh, D. S., Wadajkar, A. S., & Woodworth, G. F. (2016) · Springer eBooks · doi:10.1007/978-3-319-49864-5_13
Future Horizons and New Target Class Opportunities
Wu, H., Webster, C. I., Paterson, J., Guillard, S., Jackson, R., & Minter, R. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527699124.ch21
Otimização da síntese e desenvolvimento de sistemas nanoparticulados poliméricos e lipossomais para aplicações em células derivadas do sistema nervoso central.
Listik, E. (2018) · doi:10.11606/d.42.2018.tde-12072017-151204
Novel delivery methods bypassing the blood-brain and blood-tumor barriers
Aaron, A. D. (2015)
Bypassing the Blood-Brain Barrier to Treat Brain Cancer: A Systematic Review of the Efficacy of Carmustine Wafer Implant Therapy
Tsivis, P., & Sharobim, M. (2021) · Medical Student Research Journal · doi:10.15404/msrj/08.2021.198
Data from Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma
Dmello, C., Sonabend, A., Arrieta, V. A., Zhang, D. Y., Kanojia, D., Chen, L., Gould, A., Zhang, J., Kang, S. J., Winter, J., et al. (2023) · doi:10.1158/1078-0432.c.6531036
Data from Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma
Dmello, C., Sonabend, A., Arrieta, V. A., Zhang, D. Y., Kanojia, D., Chen, L., Gould, A., Zhang, J., Kang, S. J., Winter, J., et al. (2023) · doi:10.1158/1078-0432.c.6531036.v1
Overcoming the blood-brain barrier as a factor for increasing the efficiency of drug therapy for glioblastoma
Stepanov, I. A., Beloborodov, V. A., & Shameeva, M. A. (2023) · P A Herzen Journal of Oncology · doi:10.17116/onkolog20231202156
Basic concepts and levels of drug targeting
Mishra, M., Muley, A., Otavi, S., Pawar, B., Gupta, R., & Tekade, R. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33366-8.00010-5
Nanomedicine for Glioblastoma: Cutting-Edge Advances and Persistent Challenges
Kumar, L. A., Katta, S., Debata, J., Padhy, G. K., Mohanty, D., & Babu, S. (2025) · Journal of Bio-X Research · doi:10.34133/jbioxresearch.0065
Hindrance in immunotherapy resistant glioblastoma
Bhushan, R., Abubakar, M., Chavan, P. R., Pandey, R., Jamadade, M. S., Murti, K., & Kumar, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33910-3.00005-4
Etude du récepteur d’endocytose LRP1 dans les adénocarcinomes coliques : caractéristiques cliniques, pathologiques et moléculaires associées et valeur pronostique
Boulagnon‐Rombi, C. (2017) · theses.fr (ABES) · doi:10.70675/c907fd83z8cf9z4eb1z904bz91bbe9f6e21f
De l’ifosfamide au géranyloxy-ifosfamide : pharmacomodulation pour cibler et moduler l’immunité
Delahousse, J. (2019) · theses.fr (ABES) · doi:10.70675/516a5d4ez81ccz485azbe9cze077be422c4a
Functionalized-Cucurbit[n]urils : advanced drug carriers
Yang, X. (2020) · theses.fr (ABES) · doi:10.70675/df130d6bzf182z45e3zab34z746fb6b378fc
Rôle de LRP-1 dans la prolifération des cellules issues de cancer du côlon en matrice tridimensionnelle de collagène de type I
Le, C. (2020) · theses.fr (ABES) · doi:10.70675/516cfb73z4ed1z4894z8505z97a93287b285
Improved brain penetration of neurotensin(8–13) via blood-brain barrier shuttle conjugation underlies strong analgesia
Lagard, C., Côté, J., Meneboo, N., Barreto, S., Desgagné, M., Beaulieu, S., Larocque, A., Besserer‐Offroy, É., Belleville, K., Kirby, K., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119551
The Role of LRP1 in Glioma Progression and Therapeutic Targeting: A Narrative Review
Alhujaily, M. M. (2026) · Cells · doi:10.3390/cells15131163
Targeting Integrins in Immunity: Precision Matters for Therapeutic Interventions
Ahmed, A. U. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl47669
Precision engineering of nanocarriers for transport across complex biological barriers
Acharya, R., Komedchikova, E., Choi, Y., Yang, J., Kim, J., Son, J., Jang, J., Lee, H., Kadonosono, T., & 최종훈 (2026) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2026.100691
Shuttle systems for delivering antibody therapeutics across the BBB for the treatment of Alzheimer’s disease
Impelman, K., & An, Z. (2026) · npj Dementia · doi:10.1038/s44400-026-00152-1
Beyond Tumor Accumulation in Oncology Peptide Drug Conjugates: A Critical Narrative Review of Release-Competent Exposure and a Stage-Gated Translational Roadmap
Kızılkurtlu, A. A., Çiftçi, F., & Yılmaz, Ö. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18111372

Authors: Drappatz, J., Brenner, A., Wong, E. T., Eichler, A., Schiff, D., Groves, M. D., Mikkelsen, T., Rosenfeld, S., Sarantopoulos, J., Meyers, C. A., Fielding, R. M., Elian, K., Wang, X., Lawrence, B., Shing, M., Kelsey, S., Castaigne, J. P., & Wen, P. Y.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Drappatz, Jan
Brenner, Andrew
Wong, Eric T.
Schiff, David
Mikkelsen, Tom
Sarantopoulos, John
Fielding, Robert M.
Wang, Xiaolin
Wen, Patrick Y.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2013-03-14
Volume: 19
Issue: 6
Pages: 1567-1576
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-12-2481
OpenAlex: W2111631341
Cited by: 190
References: 51
Citations by year: 2026: 11 · 2025: 16 · 2024: 15 · 2023: 16 · 2022: 22 · 2021: 15 · 2020: 17 · 2019: 19 · 2018: 12 · 2017: 6 · 2016: 15 · 2015: 18 · 2014: 7 · 2013: 1
FWCI: 6.73
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords: recurrent malignant glioma, peptide-drug conjugates, LDL receptor-related protein 1, blood-brain barrier penetration, paclitaxel, maximum tolerated dose, pharmacokinetics, dose-limiting toxicity
MeSH terms: Adult, Aged, Antineoplastic Agents, Blood-Brain Barrier, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Glioma, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Peptides, Paclitaxel, Maximum Tolerated Dose, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Phase I Study of GRN1005 in Recurrent Malignant Glioma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks